Development andin vitro/in vivoevaluation of immediate release perindopril tablets
- 6 May 2014
- journal article
- research article
- Published by Taylor & Francis in Pharmaceutical Development and Technology
- Vol. 20 (6) , 684-693
Abstract
Perindopril erbumine (PE) is a BCS (Biopharmaceutics Classification System) class 3 drug with high solubility and low permeability. It is an inhibitor of the enzyme that converts angiotensin I (Angiotensin Converting Enzyme, ACE) into angiotensin II as well as causing the degradation of the vasodilator bradykinin into an inactive heptapeptide. The aim of this study was to develop an alternative drug product by using a different salt of perindopril and to evaluate the bioequivalence between PE, not still licensed, and perindopril arginine (PA), licensed in many countries, and to prepare PE tablets by using direct compression method. Many different formulations were prepared, among which F3-coded formulation was only selected due to releasing of 98.03% active substance at 45th minute. Bioequivalence study was planned as a cross-designed, randomized, open-labeled, single-dose, single-center study and conducted in 24 male healthy volunteers via peroral route. The results of bioequivalence study were evaluated for Perindopril and Perindoprilat according to Cmax, tmax and AUC criteria. The geometric mean ratios (90% CI) of perindopril and perindoprilat followed test and reference drug were calculated for AUC0–t and Cmax, 105.946% (100.218–112.002%) and 110.437% (102.534–118.948%); 109.542% (98.364–121.992%) and 115.729% (101.031–132.565%), respectively. The 90% confidence intervals of them were found within the standard bioequivalence range (80–125%).Keywords
This publication has 14 references indexed in Scilit:
- Bioequivalence study of two perindopril erbumine tablet formulations in healthy volunteersArzneimittelforschung, 2011
- ACE inhibition with perindopril and biomarkers of atherosclerosis and thrombosis: Results from the PERTINENT studyAtherosclerosis, 2009
- Differences in the Effect of Angiotensin-converting Enzyme Inhibitors on the Rate of Endothelial Cell Apoptosis: In Vitro and In Vivo StudiesCardiovascular Drugs and Therapy, 2007
- Acidity, lipophilicity, solubility, absorption, and polar surface area of some ACE inhibitorsChemical Papers, 2007
- First LC–MS/MS electrospray ionization validated method for the quantification of perindopril and its metabolite perindoprilat in human plasma and its application to bioequivalence studyJournal of Chromatography B, 2006
- The pharmacokinetics of perindoprilat in normal volunteers and patients: Influence of age and disease stateEuropean Journal of Pharmaceutical Sciences, 2005
- Effects of perindopril treatment on hemostatic function in patients with essential hypertension in relation to angiotensin converting enzyme (ACE) and plasminogen activator inhibitor-1 (PAI-1) gene polymorphismsNutrition, Metabolism and Cardiovascular Diseases, 2004
- Dosage considerations with perindopril for systemic hypertensionThe American Journal of Cardiology, 2001
- The pharmacokinetics of perindopril in patients with liver cirrhosis.British Journal of Clinical Pharmacology, 1992
- Single dose pharmacokinetics of perindopril and its metabolites in hypertensive patients with various degrees of renal insufficiency.British Journal of Clinical Pharmacology, 1991